• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 14.75
  • VXN 19.84
  • VXO 16.03
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
CRIS (Curis Inc.)
Last Trade 1.57 Dividend/Share 0 PE Ratio -1.55
Date May 22-2019 Dividend Yield 0.000 Return on Assets -56.95
Change 0.02 ExDividend Date 0 Return on Capital null
Bid null Latest EPS -0.99 Price/Sale 5.071
Ask null LatestEPS Date 2018-12-31 Price to Book 44.51
Volume null EPS ttm -1.010 Institutional % 30.1
Avg Volume 0.17M Shares Outstanding 33.15M Insider % null
Open 1.53 Float 30.85M Short Ratio null
Prev Close 1.55 Return On Equity 11503.78 5 Year Change % -0.827
High 1.59 Consensus EPS 0 2 Year Change % -0.820
Low 1.509 No. of Estimate 0.000 1 Year Change % -0.311
52 Week High 3.3324 EPS Surprise $ null YTD Change % 0.912
52 Week Low 0.6 EPS Surprise Percent 0 6 Month Change % 0.256
52 Week Change -41.165 EBITDA 0M 3 Month Change % 0.414
50 Day MA 1.8337 Revenue 0M 1 Month Change % -0.147
200 Day MA Gross Profit 0M 5 Day Change % -0.137
Market Cap 52.05M Cash 0M 30 Day Change % -0.259
Beta 2.189537 Debt 0M Stock Exchange NASDAQ Global Market
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, under collaboration with Genentech, Inc., is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase, epidermal growth factor receptor, and epidermal growth factor receptor 2. In addition, Curis has a development candidate, Debio 0932, which is a Heat Shock Protein 90 or Hsp90 inhibitor. The company holds a license agreement with Debiopharm related to its Hsp90 technologies. Further, it involves in preclinical testing for the development of candidates from its targeted cancer programs. The company was founded in 2000 and is based in Cambridge, Massachusetts.